Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

Peer Review reports

Original Submission
29 Apr 2022	Submitted	Original manuscript
21 Jun 2022	Reviewed	Reviewer Report - Kirsty Loudon
11 Jul 2022	Author responded	Author comments - Sina M Coldewey
Resubmission - Version 2
11 Jul 2022	Submitted	Manuscript version 2
Publishing
18 Jul 2022	Editorially accepted
2 Sep 2022	Article published	10.1186/s13063-022-06566-5

Back to article page